{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:06:26Z","timestamp":1792026386718,"version":"4.4.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["por-journal.com"],"crossmark-restriction":true},"short-container-title":["Pathol. Oncol. Res."],"abstract":"<jats:p>Acute myeloid leukemia (AML) represents an aggressive hematopoietic malignancy with a prognosis inferior to that of other leukemias. Recent targeted therapies offer new opportunities to achieve better treatment outcomes. However, due to the complex heterogeneity of AML, its prognosis remains dismal. In this study, we first identified the correlation between high expression of BRD4 and overall survival of patients with AML. Targeted degradation of BRD2, BRD3, and BRD4 proteins by dBET1, a proteolysis-targeting chimera (PROTAC) against the bromodomain and extra-terminal domain (BET) family members, showed cytotoxic effects on Kasumi (AML1-ETO), NB4 (PML-RARa), THP-1 (MLL-AF9), and MV4-11 (MLL-AF4) AML cell lines representing different molecular subtypes of AML. Furthermore, we determined that dBET1 treatment arrested cell cycling and enhanced apoptosis and c-MYC was identified as the downstream target. Collectively, our results indicated that dBET1 had broad anti-cancer effects on AML cell lines with different molecular lesions and provided more benefits to patients with AML.<\/jats:p>","DOI":"10.3389\/pore.2022.1610447","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T10:08:56Z","timestamp":1656324536000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":34,"title":["A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia Cells"],"prefix":"10.3389","volume":"28","author":[{"given":"Kunlong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinran","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zimu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihui","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanjuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuiyan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoyan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 Revision of the World Health Organization (WHO) Classification of Myeloid Neoplasms and Acute Leukemia: Rationale and Important Changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/nejmra1406184","article-title":"Acute Myeloid Leukemia","volume":"373","author":"Dohner","year":"2015","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute Myeloid Leukemia: Current Progress and Future Directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.clml.2014.08.006","article-title":"Progress in Acute Myeloid Leukemia","volume":"15","author":"Kadia","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B5","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and Management of Acute Myeloid Leukemia in Adults: Recommendations from an International Expert Panel, on Behalf of the European LeukemiaNet","volume":"115","author":"Dohner","year":"2010","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/ajh.23834","article-title":"Acute Myeloid Leukemia: 2014 Update on Risk-Stratification and Management","volume":"89","author":"Estey","year":"2014","journal-title":"Am J Hematol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.critrevonc.2016.12.004","article-title":"Frontline Treatment of Acute Myeloid Leukemia in Adults","volume":"110","author":"Tamamyan","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1182\/blood-2017-01-760595","article-title":"Molecular Synergy Underlies the Co-occurrence Patterns and Phenotype of NPM1-Mutant Acute Myeloid Leukemia","volume":"130","author":"Dovey","year":"2017","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3324\/haematol.2019.240754","article-title":"Potential Targeting of FLT3 Acute Myeloid Leukemia","volume":"106","author":"Ambinder","year":"2021","journal-title":"Haematologica"},{"key":"B10","doi-asserted-by":"publisher","first-page":"822","DOI":"10.3324\/haematol.2017.183525","article-title":"Clinical Relevance of IDH1\/2 Mutant Allele burden during Follow-Up in Acute Myeloid Leukemia. A Study by the French ALFA Group","volume":"103","author":"Ferret","year":"2018","journal-title":"Haematologica"},{"key":"B11","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1200\/jco.2015.61.1947","article-title":"Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric T(8;21)-AML: Results from an International Retrospective Study by the International Berlin-Frankfurt-Munster Study Group","volume":"33","author":"Klein","year":"2015","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"584974","DOI":"10.3389\/fonc.2020.584974","article-title":"Targeting Bcl-2 Proteins in Acute Myeloid Leukemia","volume":"10","author":"Wei","year":"2020","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 Mutations in the Origin and Evolution of Therapy-Related Acute Myeloid Leukaemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1158\/1535-7163.mct-16-0876","article-title":"FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions","volume":"16","author":"Larrosa-Garcia","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21041537","article-title":"Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML","volume":"21","author":"Lam","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1056\/NEJMra1112635","article-title":"Targeting Epigenetic Readers in Cancer","volume":"367","author":"Dawson","year":"2012","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.molcel.2014.05.016","article-title":"The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition","volume":"54","author":"Shi","year":"2014","journal-title":"Mol Cel"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.molcel.2015.04.011","article-title":"BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia","volume":"58","author":"Roe","year":"2015","journal-title":"Mol Cel"},{"key":"B19","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1158\/2159-8290.cd-17-0605","article-title":"BET Proteins as Targets for Anticancer Treatment","volume":"8","author":"Stathis","year":"2018","journal-title":"Cancer Discov"},{"key":"B20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41392-020-00384-4","article-title":"The BET Family in Immunity and Disease","volume":"6","author":"Wang","year":"2021","journal-title":"Sig Transduct Target Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1073\/pnas.1422165112","article-title":"An In-Tumor Genetic Screen Reveals that the BET Bromodomain Protein, BRD4, Is a Potential Therapeutic Target in Ovarian Carcinoma","volume":"112","author":"Baratta","year":"2015","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B22","doi-asserted-by":"publisher","first-page":"9545","DOI":"10.1073\/pnas.1121119109","article-title":"Functional Genomics Identifies Therapeutic Targets for MYC-Driven Cancer","volume":"109","author":"Toyoshima","year":"2012","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B23","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nature10334","article-title":"RNAi Screen Identifies Brd4 as a Therapeutic Target in Acute Myeloid Leukaemia","volume":"478","author":"Zuber","year":"2011","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.cell.2015.11.062","article-title":"Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance","volume":"164","author":"Marcotte","year":"2016","journal-title":"Cell"},{"key":"B25","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET Bromodomain Inhibition as a Therapeutic Strategy to Target C-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"B26","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41392-019-0101-6","article-title":"PROTACs: Great Opportunities for Academia and Industry","volume":"4","author":"Sun","year":"2019","journal-title":"Sig Transduct Target Ther"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/anie.201507978","article-title":"Small-Molecule PROTACS: New Approaches to Protein Degradation","volume":"55","author":"Toure","year":"2016","journal-title":"Angew Chem Int Ed Engl"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1126\/science.aab1433","article-title":"Drug Development. Phthalimide Conjugation as a Strategy for In Vivo Target Protein Degradation","volume":"348","author":"Winter","year":"2015","journal-title":"Science. Drug Dev"},{"key":"B29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/leu.2016.163","article-title":"Subtype-specific Patterns of Molecular Mutations in Acute Myeloid Leukemia","volume":"31","author":"Rose","year":"2017","journal-title":"Leukemia"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.3324\/haematol.2018.201483","article-title":"Proteolysis Targeting Chimeric Molecules as Therapy for Multiple Myeloma: Efficacy, Biomarker and Drug Combinations","volume":"104","author":"Lim","year":"2019","journal-title":"Haematologica"},{"key":"B31","doi-asserted-by":"publisher","first-page":"E5086","DOI":"10.1073\/pnas.1712363115","article-title":"Targetable BET Proteins- and E2F1-dependent Transcriptional Program Maintains the Malignancy of Glioblastoma","volume":"115","author":"Xu","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B32","doi-asserted-by":"publisher","first-page":"100141","DOI":"10.1016\/j.xinn.2021.100141","article-title":"clusterProfiler 4.0: A Universal Enrichment Tool for Interpreting Omics Data","volume":"2","author":"Wu","year":"2021","journal-title":"Innovation (Camb)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3274","DOI":"10.7150\/jca.33110","article-title":"The Dual Role of BI 2536, a Small-Molecule Inhibitor that Targets PLK1, in Induction of Apoptosis and Attenuation of Autophagy in Neuroblastoma Cells","volume":"11","author":"Li","year":"2020","journal-title":"J Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12935-021-01908-w","article-title":"BRD4 PROTAC Degrader ARV-825 Inhibits T-Cell Acute Lymphoblastic Leukemia by Targeting 'Undruggable' Myc-Pathway Genes","volume":"21","author":"Wu","year":"2021","journal-title":"Cancer Cel Int"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143606","article-title":"Functional Roles of Bromodomain Proteins in Cancer","volume":"13","author":"Boyson","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B36","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41392-020-00361-x","article-title":"Targeting Multiple Signaling Pathways: the New Approach to Acute Myeloid Leukemia Therapy","volume":"5","author":"Carter","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00280-015-2766-z","article-title":"Direct and Indirect Targeting of MYC to Treat Acute Myeloid Leukemia","volume":"76","author":"Brondfield","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and Management of AML in Adults: 2017 ELN Recommendations from an International Expert Panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40364-020-00196-2","article-title":"Advances in Targeted Therapy for Acute Myeloid Leukemia","volume":"8","author":"Yu","year":"2020","journal-title":"Biomark Res"},{"key":"B40","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41375-021-01164-x","article-title":"Two Decades of Targeted Therapies in Acute Myeloid Leukemia","volume":"35","author":"Cucchi","year":"2021","journal-title":"Leukemia"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1182\/bloodadvances.2019000174","article-title":"Gilteritinib: Potent Targeting of FLT3 Mutations in AML","volume":"4","author":"Levis","year":"2020","journal-title":"Blood Adv"},{"key":"B42","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-021-01111-4","article-title":"MYC: a Multipurpose Oncogene with Prognostic and Therapeutic Implications in Blood Malignancies","volume":"14","author":"Ahmadi","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1182\/blood.2019001745","article-title":"BCL6 Maintains Survival and Self-Renewal of Primary Human Acute Myeloid Leukemia Cells","volume":"137","author":"Kawabata","year":"2021","journal-title":"Blood"}],"container-title":["Pathology and Oncology Research"],"original-title":[],"link":[{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2022.1610447\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T10:09:03Z","timestamp":1656324543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2022.1610447\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,27]]},"references-count":43,"alternative-id":["10.3389\/pore.2022.1610447"],"URL":"https:\/\/doi.org\/10.3389\/pore.2022.1610447","relation":{},"ISSN":["1532-2807"],"issn-type":[{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,27]]},"article-number":"1610447"}}